The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of
The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent.
대표청구항▼
1. A self-supporting layered film dosage composition comprising: at least a first region including:a. a polymeric carrier matrix;b. a therapeutically effective amount of apomorphine or a pharmaceutically acceptable salt thereof as an agonist; andc. a buffer,wherein the ratio of said buffer to apomor
1. A self-supporting layered film dosage composition comprising: at least a first region including:a. a polymeric carrier matrix;b. a therapeutically effective amount of apomorphine or a pharmaceutically acceptable salt thereof as an agonist; andc. a buffer,wherein the ratio of said buffer to apomorphine or a pharmaceutically acceptable salt thereof is from about 2:1 to about 1:5, and at least a second region,wherein the at least first region and the at least second region are arranged in a layered film dosage; and said layered film dosage provides a local pH of the agonist containing region is between about 5 to about 9;and wherein said self-supporting layered film dosage composition disperses in an oral cavity in about 30 minutes or less. 2. The self-supporting film dosage composition of claim 1, wherein said composition contains from about 2 to about 16 mg of apomorphine or a pharmaceutically acceptable salt thereof. 3. The self-supporting film dosage composition of claim 1, wherein said composition disperses and dissolves in the oral cavity between about 1 minute and about 3 minutes. 4. The self-supporting film dosage composition of claim 1, wherein said composition has a thickness of from 0.1 to 10 mils. 5. The self-supporting film dosage composition of claim 1, wherein said polymeric carrier matrix comprises polyethylene oxide, pullulan, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, carboxymethyl cellulose, polyvinyl alcohol, sodium alginate, polyethylene glycol, xanthan gum, tragancanth gum, guar gum, acacia gum, arabic gum, polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl copolymers, starch, gelatin, or a combination thereof. 6. The self-supporting film dosage composition of claim 1, wherein said composition further comprises an FD&C coloring agent. 7. The self-supporting film dosage composition of claim 1, wherein said composition further comprises glycerol, glycerol monoacetate, diacetate or triacetate, triacetin, polysorbate, cetyl alcohol, propylene glycol, sorbitol, sodium diethylsulfosuccinate, triethyl citrate, or tributyl citrate. 8. The self-supporting film dosage composition of claim 1, wherein said composition further comprises glycerol. 9. The self-supporting film dosage composition of claim 1, wherein said composition further comprises a sweetener. 10. The self-supporting film dosage composition of claim 9, wherein said sweetener is sucralose. 11. The self-supporting film dosage composition of claim 1, wherein said self-supporting film dosage composition has a thickness of from 0.1 to 10 mils. 12. The self-supporting film dosage composition of claim 1 wherein the dosage contains regions of differing dissolution rates. 13. The self-supporting film dosage composition of claim 1 wherein the composition is a dual region product. 14. The self-supporting film dosage composition of claim 1 wherein the buffer includes a first buffering system. 15. The self-supporting film dosage composition of claim 14 wherein the self-supporting film dosage composition further includes a second buffering system. 16. A self-supporting layered film dosage composition comprising: at least a first region including:a polymeric carrier matrix comprising polyethylene oxide, pullulan, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, carboxymethyl cellulose, polyvinyl alcohol, sodium alginate, polyethylene glycol, xanthan gum, tragancanth gum, guar gum, acacia gum, arabic gum, polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl copolymers, starch, gelatin, or a combination thereof;a therapeutically effective amount of apomorphine or a pharmaceutically acceptable salt thereof as an agonist, anda buffer,wherein the ratio of said buffer to apomorphine or a pharmaceutically acceptable salt thereof is from about 2:1 to about 1:5, and at least a second region,wherein the at least first region and the at least second region are arranged in a layered film dosage; and said layered film dosage provides a local pH of the agonist containing region is between about 5 to about 9;and wherein said self-supporting layered film dosage composition disperses in an oral cavity in about 30 minutes or less. 17. The self-supporting film dosage composition of claim 16, wherein said composition further comprises glycerol, glycerol monoacetate, diacetate or triacetate, triacetin, polysorbate, cetyl alcohol, propylene glycol, sorbitol, sodium diethylsulfosuccinate, triethyl citrate, or tributyl citrate and wherein said composition further comprises a sweetener. 18. The self-supporting film dosage composition of claim 16, wherein said composition further comprises an FD&C coloring agent. 19. The self-supporting film dosage composition of claim 16, wherein said composition further comprises glycerol. 20. The self-supporting film dosage composition of claim 16, wherein said sweetener is sucralose. 21. The self-supporting film dosage composition of claim 16, wherein the composition comprises about 2 to about 16 mg of apomorphine or a pharmaceutically acceptable salt thereof. 22. The self-supporting film dosage composition of claim 16, wherein said composition disperses and dissolves in the oral cavity between about 1 minute and about 3 minutes. 23. The self-supporting film dosage composition of claim 16, wherein said self-supporting film dosage composition has a thickness of from 0.1 to 10 mils. 24. The self-supporting film dosage composition of claim 16 wherein the dosage contains regions of differing dissolution rates. 25. The self-supporting film dosage composition of claim 16 wherein the composition is a dual region product. 26. The self-supporting film dosage composition of claim 16 wherein the buffer includes a first buffering system. 27. The self-supporting film dosage composition of claim 26 wherein the self-supporting film dosage composition further includes a second buffering system. 28. A self-supporting layered film dosage composition comprising: at least a first region including:a polymeric carrier matrix comprising polyethylene oxide, pullulan, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, carboxymethyl cellulose, polyvinyl alcohol, sodium alginate, polyethylene glycol, xanthan gum, tragancanth gum, guar gum, acacia gum, arabic gum, polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl copolymers, starch, gelatin, or a combination thereof; anda therapeutically effective amount of apomorphine or a pharmaceutically acceptable salt thereof as an agonist anda buffer,wherein the ratio of said buffer to apomorphine or a pharmaceutically acceptable salt thereof is from about 2:1 to about 1:5,and at least a second region,wherein the at least first region and the at least second region are arranged in a layered film dosage; and said layered film dosage provides a local pH of the agonist containing region is between about 5 to about 9;and wherein the film is mucoadhesive to the sublingual mucosa or the buccal mucosa;wherein said composition further comprises glycerol and sucraloseand wherein said self-supporting layered film dosage composition disperses in an oral cavity in about 30 minutes or less. 29. The self-supporting film dosage composition of claim 28 wherein the dosage contains regions of differing dissolution rates. 30. The self-supporting film dosage composition of claim 28 wherein the composition is a dual region product. 31. The self-supporting film dosage composition of claim 28 wherein the buffer includes a first buffering system. 32. The self-supporting film dosage composition of claim 31 wherein the self-supporting film dosage composition further includes a second buffering system.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (129)
Altwirth Oskar (Oberach 37 A-4950 Altheim ATX), Adherent insert for artificial teeth and process of manufacturing the insert.
Babaian Eduard A. (Moscow SUX) Gerasimova Galina A. (Moscow SUX) Davydov Anatoly B. (Moscow SUX) Utyamyshev Rustam I. (Moscow SUX) Khromov Gennady L. (Moscow SUX) Metelitsa Vladimir I. (Moscow SUX) V, Antianginal film and method of treating ischemic heart disease.
Hijiya Hiromi (Okayama JPX) Miyake Toshio (Okayama JPX), Association complex comprising pullulan and polyethylene glycol, and preparation and uses of the same.
Rel Bernhard (Knigstein/Taunus DEX) Petri Walter (Niedernhausen/Taunus DEX), Base for mucosal and denture adhesive pastes, a process for the preparation thereof, and pastes having this base.
Schiraldi Michael T. (East Brunswick NJ) Perl Martin M. (Brooklyn NY) Rubin Howard (Rockaway NJ), Bioadhesive extruded film for intra-oral drug delivery and process.
Schiraldi Michael T. (East Brunswick NJ) Perl Martin M. (Brooklyn NY) Rubin Howard (Rockaway NJ), Bioadhesive extruded film for intra-oral drug delivery and process.
Michael A. Repka ; Staci L. Repka ; James W. McGinity, Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof.
Norton Richard L. (Fort Collins CO) Knight Stephen Michael Gregory (Fort Collins CO) Tipton Arthur J. (Birmingham AL), Biodegradable polymeric composition.
Fischel-Ghodsian Fariba (2122 Century Park La. ; #104 Los Angeles CA 90067), Device for controlled release of vaporous medications through nasal route.
Hymes Alan C. (Minnetonka MN) Ong Lincoln T. (Minnetonka MN) Persons Garry R. (Edina MN), Drug dispensing device for transdermal delivery of medicaments.
Eury Robert P. (Cupertino CA) Garguilo Darlene (Fremont CA) Villareal Plaridel (San Jose CA), Drug loaded polymeric material and method of manufacture.
Jevne Allan H. (Anoka MN) Vegoe Brett R. (Brooklyn Park MN) Holmblad Carolann M. (Cambridge MN) Cahalan Patrick T. (Champlin MN), Hydrophilic pressure sensitive biomedical adhesive composition.
Broberg Berndt F. J. (Sdertlje SEX) Evers Hans C. A. (Sdertlje SEX), Local anesthetic mixture for topical application and method for obtaining local anesthesia.
Leusner Bernd (Leverkusen DEX) Heiss Rdiger (Grefrath DEX) Pelster Bernd (St. Augustin DEX) Fischer Wolfgang (Bergisch Gladbach DEX) Ohm Ulrich (Odenthal DEX), Medicaments for the region of the oral cavity.
Nagai Tsuneji (Chofu JPX) Machida Yoshiharu (Kawasaki JPX) Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX), Method and preparation for administration to the mucosa of the oral or nasal cavity.
Kizawa Hidenori (Tokyo JPX) Fujiyama Norimasa (Tokyo JPX) Kobayashi Jitsuo (Kanagawa JPX) Ito Akinori (Niigata JPX), Mucous membrane-adhering film preparation and process for its preparation.
Sorrentino James V. (Wilton CT) Kelleher William J. (Storrs CT) Moye Jeanne O. (Fairfield CT), Pharmaceutical compositions containing dyclonine HC1 and phenol.
Santus Giancarlo (Milan ITX) Bottoni Giuseppe (Bergamo ITX) Sala Giovanni (Verona ITX), Pharmaceutical controlled-release composition with bioadhesive properties.
Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX) Noguchi Toshihide (Tokyo JPX) Izumizawa Katsunori (Yokohama JPX) Kinoshita ; deceased Shiro (late of Tokyo JPX by Kimiko Kinoshita ; Atsuhiro Kinosh, Pharmaceutical preparation for remedy of periodontal disease and process for production thereof.
Vert Michel (Mont-Saint-Aignan FRX) Mauduit Jacques (Bacqueville En Caux FRX) Bukh Niels (Hellerup DKX), Polylactic acid-based implant susceptible of bioresorption containing and antibiotic.
Schmidt Wolfgang (Reembroden 44 D-2000 Hamburg 63 DEX), Process for producing an administration or dosage form for drugs, reagents or other active ingredients.
Horstmann Michael (Neuwied DEX) Laux Wolfgang (Dietz DEX) Hungerbach Stefan (Nortershausen DEX), Rapidly disintegrating sheet-like presentations of multiple dosage units.
Chang Yunik (Lakewood NJ) Patel Dinesh C. (Murray UT), Skin penetration enhancement using free base and acid addition salt combinations of active agents.
Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX) Yamashita Gentaro (Koganei JPX), Slow-releasing medical preparation to be administered by adhering to a wet mucous surface.
Wheatley Margaret A. (Arlington MA) Langer Robert S. (Somerville MA) Eisen Herman N. (Waban MA), System for delayed and pulsed release of biologically active substances.
AF Ekenstam Bo T. (Box 721 Hjlteby SEX S-440 74) Aberg Gunnar A. K. (Utsiktsvgen 7 Falkenberg SEX S-311 00), Therapeutically active, substituted piperidines and pyrrolidines therapeutic compositions thereof and methods of use the.
Heiber Sonia J. (Salt Lake City UT) Ebert Charles D. (Salt Lake City UT) Dave Sirish C. (Salt Lake City UT), Transmucosal delivery of macromolecular drugs.
Biegajski James E. (Foster City CA) Venkatraman Subbu S. (Palo Alto CA) Scott Ann M. (Mountain View CA), Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavi.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.